



ASX ANNOUNCEMENT

2 NOVEMBER 2022

## **SPONSORED RESEARCH AGREEMENT WITH CASE WESTERN UNIVERSITY TO ADVANCE CORE NK PORTFOLIO**

- Investor webinar to be held at 9am AEDT, Thursday 3 November – [register here](#)

Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a sponsored research agreement (SRA) with Case Western Reserve University (CWRU) to further advance Chimeric’s NK cell therapy portfolio.

The research program at CWRU will be led by Dr David Wald, inventor of the CORE NK technology. Through this research collaboration, Dr Wald and his laboratory will work closely with Chimeric to advance multiple next-generation NK cell products through preclinical development, including CHM 0301 (Next-Generation CORE-NK Platform), CHM 1301 (Chlorotoxin CAR NK), CHM 2301 (CDH17 CAR NK), and CHM 3301 (undisclosed CAR NK).

Chimeric’s NK cell therapy portfolio foundational asset, CHM 0201 (CORE NK platform) was invented and developed by Dr Wald at Case Western. CHM 0201 was studied in a phase 1 clinical trial at Seidman Cancer Center in Ohio with promising outcomes that were published<sup>1</sup> earlier this year. All key endpoints of the study were achieved, including safety with no graft versus host disease, cell persistence and cell expansion. In addition, an encouraging efficacy signal was demonstrated, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained through to 15 months at time of study publication.

“With the encouraging clinical data seen with CHM 0201 (CORE NK cell platform) we are very excited to be enhancing our collaboration with Dr Wald and his team at Case Western. By building upon Dr Wald’s NK cell scientific experience and expertise we believe we will be able to advance NK cell therapies to benefit patients in multiple disease areas in the future” said Jennifer Chow, CEO and Managing Director Chimeric Therapeutics.

Dr Wald is an Associate Professor, Department of Pathology, School of Medicine, CWRU, a member of the Immune Oncology Program, Case Comprehensive Cancer Center, and the Associate Director for Basic Research, University Hospitals, Wesley Center for Immunotherapy.

Under the SRA, Chimeric receives the exclusive option to license intellectual property created by CWRU as part of the sponsored research.



The agreement is outcomes based on research aims for an initial period estimated to be two years, which may be extended by mutual agreement of the parties.

### **Investor webinar**

Chimeric Therapeutics CEO and Managing Director Jennifer Chow, CMO Dr Jason B Litten and Dr David Wald will hold an investor webinar tomorrow, Thursday 3 November 2022 at 9am AEDT to elaborate on this announcement and take questions.

Click the link below to register:

[https://us02web.zoom.us/webinar/register/WN\\_TEILee0TTPKGK62NjHKXBw](https://us02web.zoom.us/webinar/register/WN_TEILee0TTPKGK62NjHKXBw)

After registering, you will receive a confirmation email about how to join the webinar. A recording of the webinar will be available at the same link shortly after the conclusion of the session.

<sup>1</sup> ASX announcement, 7 March 2022

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell



platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)